Peripheral neurotoxicity induced by docetaxel

Neurology

Volumn 46, Issue 1, 1996, Pages 104-108

  Hilkens, P H E ^a   Verweij, J ^a   Stoter, G ^a   Vecht, Ch J ^a   Van Putten, W L J ^a   Van Den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; METHYLPREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; VIBRATION SENSE;

EID: 0029888797     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.104     Document Type: Article

References (24)

1. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-386.
2. Piccart MJ, Gore M, ten Bokkel-Huinink W, et al. Taxotere: an active new drug for the treatment of advanced ovarian carcinoma. Proc ASCO 1993;12:258.
3. Aapro M, Pujade-Lauraine E, Lhomme C, et al. Phase II study of taxotere in ovarian cancer. Proc ASCO 1993;12:256.
4. Trudeau ME, Eisenhauer E, Lofters W, et al. Phase II study of taxotere as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada clinical trials group study. Proc ASCO 1993;12:64.
5. Seidman AD, Hudis C, Crown JPA, et al. Phase II evaluation of taxotere as initial chemotherapy for metastatic breast cancer. Proc ASCO 1993;12:63.
6. Fumoleau P, Chevallier B, Kerbrat P, et al. First-line chemotherapy with taxotere in advanced breast cancer: a phase II study of the EORTC clinical screening group. Proc ASCO 1993;12:56.
7. Valero V, Esparza L, Holmes F, et al. Phase II study of taxotere in refractory metastatic breast cancer. Proc ASCO 1993; 12:96.
8. ten Bokkel-Huinink W, van Oosterom A, Piccart M, et al. Taxotere in advanced breast cancer. A phase II trial of the EORTC early clinical trials group. Proc ASCO 1993;12:70.
9. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group. Eur J Cancer 1994;30A: 1061-1064.
10. Fossella F, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:1238-1244.
11. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-1237.
12. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer 1994;30A: 1058-1060.
13. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-373.
14. Goldberg JM, Lindblom U. Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 1979;42:793-803.
15. Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FGI. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989;93: 167-174.
16. Gerritsen van der Hoop R, Vecht ChJ, Van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322:89-94.
17. Hovestadt A, Van der Burg MEL, Verbiest HBC, Van Putten WLJ, Vecht ChJ. The course of neuropathy after cessation of cisplatin treatment, combined with org 2766 or placebo. J Neurol 1992;239:143-146.
18. van Gerven JMA, Moll JWB, van den Bent MJ, et al. Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-1077.
19. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53;523-527.
20. Extra JM, Rousseau F, Bruno R, Clavel F, LeBail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976, NSC 628503) given as a short infusion. Cancer Res 1993;53: 1037-1042.
21. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-958.
22. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;108-111.
23. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66:1117-1123.
24. Boogerd W, ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJJF, van der Sande JJ. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990;9:255-263.